Moderna Stock Gains on Encouraging Flu Vaccine Data

Key Takeaways Moderna's mRNA-1010 flu shot showed 26.6% better efficacy than GSK's in a phase III trial. Efficacy was strong across strains and age groups, with 27.4% rVE in seniors aged 65 and older. The results may aid future FDA submissions for mRNA-1010 and support the combo vaccine mRNA-1083.Moderna (MRNA) announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc (GSK) in a phase III efficacy stu ...